← Research library

Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke

Randomized study in people · 2014

What was studied
ESCORT; 272 acute ischemic-stroke patients
Main finding
Double-blind placebo-controlled comparison of repeated Cortexin, one course followed by placebo, and placebo. Authors reported functional and pharmacoeconomic benefits.

Reported findings and study design

272 acute-stroke patients in a multicenter double-blind placebo comparison. Three treatment sequences; Cortexin 10 mg IM three times daily, with one or two ten-day courses; 70-day observation and four visits.

Population or model ESCORT; 272 acute ischemic-stroke patients

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Best reported treatment sequenceTwo Cortexin coursesExact scale scores and arm-level results absent from abstract

This is the 272-participant Cortexin trial included in later reviews, not another independent trial population.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Read alongside the independent 2023 Cochrane assessment; favorable scales do not establish mortality benefit.
  • The related ESCORT publications describe one trial.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Randomized trialEnglish abstract

Aliferova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MIu, Meshkova KS, Salimov KA, Stakhovskaia LV, Chefranova ZhIu, Shamalov NA. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke Zh Nevrol Psikhiatr Im S S Korsakova 114(4):41-46. PMID 24874316

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards